Antiviral use was associated with lower odds of long COVID
A review linked nirmatrelvir/ritonavir use during acute COVID to lower overall odds of long COVID, with substantial study differences and no significant associations for several symptom categories.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Outpatients prescribed nirmatrelvir/ritonavir during acute infection had lower pooled odds of later long COVID than those who did not receive it. This association does not establish causation, and the abstract gives no absolute risk reduction. The overall finding also should not be assumed to apply equally to every long-COVID symptom.
Results varied greatly across studies. The abstract does not describe their designs, adjustment for confounding or follow-up periods, limiting causal interpretation and judgments about an individual's likely benefit.
What researchers found
Developing long COVID
Nirmatrelvir/ritonavir versus no use: treated outpatients had 0.85 times the odds of long COVID. Follow-up timing was not specified.
What the odds comparison means
Odds compare the chance of an outcome happening with the chance of it not happening. The ratio favored treatment, but the abstract lacks absolute event rates needed to judge the difference in patients' actual risk.
Symptoms without clear differences
No statistically significant differences were reported for cough, asthma, autonomic dysfunction, anxiety, post-traumatic stress disorder, sleep problems, musculoskeletal pain or smell and taste dysfunction. These findings leave associations uncertain and do not demonstrate equivalent outcomes.
The original publication
Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.
Cucunawangsih C, Ansori ANM, Vatvani AD et al.
Expert Rev Anti Infect Ther · 2026
- PubMed ID
- 41717886
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.